Business
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
CHICAGO, April 23, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2026 financial results before the open of the U.S. financial markets on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company
About this update from Xeris Biopharma Holdings, Inc.
Conference Call to be Held at 8:30 a.m. ET CHICAGO, April 23, 2026 --( BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2026 financial results before the open of the U.S. financial markets on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results. Interested parties may pre-register for the call here or via the "Events" section of the Investor Relations website. It is recommended that attendees register 15 minutes prior to the scheduled webcast. The webcast, replay and other information related to the event can be accessed on the investor website https://xerispharma.com/investor-relations . About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev ® , for the treatment of endogenous Cushing’s syndrome; Gvoke ® , a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis ® , a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol ® and XeriJect ® , for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com , or follow us on X , LinkedIn , or Instagram . View source version on businesswire.com: https://www.businesswire.com/news/home/20260423117811/en/ Contacts Xeris Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications [email protected]
View stock analysis, news, and events for Xeris Biopharma Holdings, Inc.